46 R.G. Pertwee
Maneuf YP, Brotchie JM (1997) Paradoxical action of the cannabinoid WIN 55,212-2 in stim-
ulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol
120:1397–1398
Mang CF, Erbelding D, Kilbinger H (2001) Differential effects of anandamide on acetyl-
choline release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid
receptors. Br J Pharmacol 134:161–167
Marinelli S, Vaughan CW, Christie MJ, Connor M (2002) Capsaicin activation of glutamater-
gic synaptic transmission in the rat locus coeruleus in vitro. J Physiol 543:531–540
Marinelli S, Di Marzo V, Berretta N, Matias I, Maccarrone M, Bernardi G, Mercuri NB
(2003) Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of
the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci
23:3136–3144
Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective proper-
ties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1.
J Neurochem 80:448–456
Martin B, Stevenson LA, Pertwee RG, Breivogel CS, Williams W, Mahadevan A, Razdan
RK (2002) Agonists and silent antagonists in a series of cannabinoid sulfonamides.
Symposium on the Cannabinoids. Burlington, Vermont, International Cannabinoid
Research Society, p 2
Martin BR, Thomas BF, Razdan RK (1995) Structural requirements for cannabinoid receptor
probes. In: Pertwee RG (ed) Cannabinoid receptors. Academic Press, London, pp 35–
85
Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004) Antitumor
effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines.
J Pharmacol Exp Ther 308:838–845
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabi-
noid receptor and functional expression of the cloned cDNA. Nature 346:561–564
Mauler F, Mittendorf J, Horváth E, De Vry J (2002) Characterization of the diarylether sul-
fonylester(–)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate
(BAY 38–7271) as a potent cannabinoid receptor agonist with neuroprotective proper-
ties. J Pharmacol Exp Ther 302:359–368
Mauler F, Hinz V, Augstein K-H, Fassbender M, Horváth E (2003) Neuroprotective and brain
edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38–7271. Brain
Res 989:99–111
Mechoulam R, Gaoni Y (1967) Recent advances in the chemistry of hashish. Fortschr Chem
Org Naturst 25:175–213
MechoulamR,Ben-ShabatS,HanusL,LigumskyM,KaminskiNE,SchatzAR,GopherA,
Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel
Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that
binds to cannabinoid receptors. Biochem Pharmacol 50:83–90
Mechoulam R, Fride E, Di Marzo V (1998) Endocannabinoids. Eur J Pharmacol 359:1–18
MechoulamR,PanikashviliD,ShohamiE(2002)Cannabinoidsandbraininjury:therapeutic
implications. Trends Mol Med 8:58–61
Millns PJ, Chapman V, Kendall DA (2001) Cannabinoid inhibition of the capsaicin-induced
calcium response in rat dorsal root ganglion neurones. Br J Pharmacol 132:969–971
Misner DL, Sullivan JM (1999) Mechanism of cannabinoid effects on long-term potentiation
and depression in hippocampal CA1 neurons. J Neurosci 19:6795–6805
Mo FM, Offertáler L, Kunos G (2004) Atypical cannabinoid stimulates endothelial cell mi-
gration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur J Pharmacol
489:21–27
Molderings GJ, Göthert M (1999) Imidazoline binding sites and receptors in cardiovascular
tissue. Gen Pharmacol 32:17–22
Molderings GJ, Bönisch H, Hammermann R, Göthert M, Brüss M (2002) Noradrenaline
release-inhibiting receptors on PC12 cells devoid ofα2- and CB1 receptors: similarities
to presynaptic imidazoline and edg receptors. Neurochem Int 40:157–167